![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00833456 |
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare general functioning of patients with schizophrenia treated with Seroquel SR between baseline and the last study visit. The secondary study objectives are to compare general functioning of patients with schizophrenia treated with other atypical antipsychotic medicinal products administered once daily between baseline and the last study visit, monitoring of other indicators of clinical improvement, evaluation of patient compliance and assessment of occurrence of adverse effects
Condition |
---|
Schizophrenia |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Non-Interventional Clinical Study to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia, Treated With Atypical Antipsychotics |
Estimated Enrollment: | 400 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | October 2009 |
Groups/Cohorts |
---|
1
Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
|
2
Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
patients visiting psychiatrist's practice
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Slovenia Clinical Study, Information | + 386 1 51 35 600 | gabrijela.dolenc@astrazeneca.com |
Slovenia | |
Research Site | Recruiting |
Zaplana, Slovenia |
Principal Investigator: | Peter Pregelj, MD, PhD | PREGELJ, Psihiatrično svetovanje d.o.o. |
Responsible Party: | AstraZeneca ( Meta Jeras, Mr Ph, Medical and Regulatory Affairs Manager ) |
Study ID Numbers: | NIS-NSI-SER-2008/1 |
Study First Received: | January 29, 2009 |
Last Updated: | January 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00833456 History of Changes |
Health Authority: | Slovenia: Agency for Medicinal Products - Ministry of Health |
schizophrenia Seroquel SR atypical antipsychotics assessment of functioning GAF scale |
Schizophrenia Quetiapine Tranquilizing Agents Mental Disorders Psychotropic Drugs |
Central Nervous System Depressants Psychotic Disorders Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Schizophrenia Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |